Deal Value – Talk Bio

Eli Lilly Signs Up to $2.6 Billion Deal with South Korean Biotech for RNA Medicine Delivery

3 weeks ago talkbio0Tagged cardiometabolic, Deal Value, eli lilly, LEAD platform, Metabolic Diseases, News [Publication Type], Pharma, RNAi medicines, SanegeneBio, South Korean biotech, strategic partnership

Eli Lilly; SanegeneBio; South Korean biotech; RNAi medicines; metabolic diseases; LEAD platform; strategic partnership; cardiometabolic; deal value; pharma news

NanoPhoria Secures €83.5M Series A for Heart Failure Therapy; AstraZeneca and Algen Ink Up to $555M AI Drug Discovery Pact

2 months ago talkbio0Tagged AI drug discovery, Algen Biotechnologies, AstraZeneca, Clustered Regularly Interspaced Short Palindromic Repeats, Deal Value, gene modulation, Heart failure, Immunology, nano-in-micro delivery, NanoPhoria, NP-MP1, Series A

NanoPhoria; Series A; heart failure; NP-MP1; nano-in-micro delivery; AstraZeneca; Algen Biotechnologies; AI drug discovery; immunology; CRISPR; gene modulation; deal value

Sage Therapeutics Acquired by Supernus Pharmaceuticals in $561M Deal

6 months ago talkbio0Tagged Acquisition, Biogen, Deal Value, Depression, Postpartum, Drug Industry, Supernus Pharmaceuticals, Zurzuvae

Sage Therapeutics; Supernus Pharmaceuticals; acquisition; Zurzuvae; postpartum depression; biotech; pharmaceutical industry; major depressive disorder; Biogen; deal value

Samsung Biologics Secures $1.2 Billion Production Contract, Boosting 2024 Deal Value to Over $3.3 Billion

1 year ago talkbio0Tagged Biological Factors, CDMO, Contract agreement, Deal Value, Manufacturing, production, Samsung

Samsung Biologics, CDMO, Contract Manufacturing, Biopharmaceuticals, Production Contract, 2024 Deal Value